Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Establishment and Utility of SwedAD : A Nationwide Swedish Registry for Patients with Atopic Dermatitis Receiving Systemic Pharmacotherapy

Alsterholm, Mikael ; Svedbom, Axel ; Anderson, Chris D ; Holm Sommar, Lena ; Ivert, Lina U ; Josefson, Anna ; Von Kobyletzki, Laura LU ; Lindberg, Magnus ; Lundeberg, Lena and Lundqvist, Maria , et al. (2023) In Acta Dermato-Venereologica 103. p.1-7
Abstract

SwedAD, a Swedish nationwide registry for patients with atopic dermatitis receiving systemic pharmacotherapy, was launched on 1 September 2019. We describe here the establishment of a user-friendly registry to the benefit of patients with atopic dermatitis. By 5 November 2022, 38 clinics had recorded 931 treatment episodes in 850 patients with an approximate national coverage rate of 40%. Characteristics at enrolment included median Eczema Area and Severity Index (EASI) 10.2 (interquartile range 4.0, 19.4), Patient-Oriented Eczema Measure (POEM) 18.0 (10.0, 24.0), Dermatology Life Quality Index (DLQI) 11.0 (5.0, 19.0) and Peak Itch Numerical Rating Scale-11 (NRS-11) 6.0 (3.0, 8.0). At 3 months, median EASI was 3.2 (1.0, 7.3) and POEM,... (More)

SwedAD, a Swedish nationwide registry for patients with atopic dermatitis receiving systemic pharmacotherapy, was launched on 1 September 2019. We describe here the establishment of a user-friendly registry to the benefit of patients with atopic dermatitis. By 5 November 2022, 38 clinics had recorded 931 treatment episodes in 850 patients with an approximate national coverage rate of 40%. Characteristics at enrolment included median Eczema Area and Severity Index (EASI) 10.2 (interquartile range 4.0, 19.4), Patient-Oriented Eczema Measure (POEM) 18.0 (10.0, 24.0), Dermatology Life Quality Index (DLQI) 11.0 (5.0, 19.0) and Peak Itch Numerical Rating Scale-11 (NRS-11) 6.0 (3.0, 8.0). At 3 months, median EASI was 3.2 (1.0, 7.3) and POEM, DLQI, and NRS-11 were improved. Regional coverage varied, reflecting the distribution of dermatologists, the ratio of public to private healthcare, and difficulties in recruiting certain clinics. This study highlights the importance of a nationwide registry when managing systemic pharmacotherapy of atopic dermatitis.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Humans, Dermatitis, Atopic/drug therapy, Sweden, Severity of Illness Index, Registries, Eczema, Quality of Life
in
Acta Dermato-Venereologica
volume
103
article number
adv7312
pages
1 - 7
publisher
Medical Journals Limited
external identifiers
  • scopus:85151799627
  • pmid:37021597
ISSN
1651-2057
DOI
10.2340/actadv.v103.7312
language
English
LU publication?
yes
id
f5097dc3-7b4f-4f35-a1ea-762e0bb9d70f
date added to LUP
2023-04-27 11:50:20
date last changed
2024-06-29 03:24:39
@article{f5097dc3-7b4f-4f35-a1ea-762e0bb9d70f,
  abstract     = {{<p>SwedAD, a Swedish nationwide registry for patients with atopic dermatitis receiving systemic pharmacotherapy, was launched on 1 September 2019. We describe here the establishment of a user-friendly registry to the benefit of patients with atopic dermatitis. By 5 November 2022, 38 clinics had recorded 931 treatment episodes in 850 patients with an approximate national coverage rate of 40%. Characteristics at enrolment included median Eczema Area and Severity Index (EASI) 10.2 (interquartile range 4.0, 19.4), Patient-Oriented Eczema Measure (POEM) 18.0 (10.0, 24.0), Dermatology Life Quality Index (DLQI) 11.0 (5.0, 19.0) and Peak Itch Numerical Rating Scale-11 (NRS-11) 6.0 (3.0, 8.0). At 3 months, median EASI was 3.2 (1.0, 7.3) and POEM, DLQI, and NRS-11 were improved. Regional coverage varied, reflecting the distribution of dermatologists, the ratio of public to private healthcare, and difficulties in recruiting certain clinics. This study highlights the importance of a nationwide registry when managing systemic pharmacotherapy of atopic dermatitis.</p>}},
  author       = {{Alsterholm, Mikael and Svedbom, Axel and Anderson, Chris D and Holm Sommar, Lena and Ivert, Lina U and Josefson, Anna and Von Kobyletzki, Laura and Lindberg, Magnus and Lundeberg, Lena and Lundqvist, Maria and Nylander, Elisabet and Sandström Falk, MariHelen and Shayesteh, Alexander and Sigurdardottir, Gunnthorunn and Sonesson, Andreas and Svensson, Åke and Virtanen, Marie and Vrang, Sophie and Wahlgren, Carl-Fredrik and Bradley, Maria and Johansson, Emma K}},
  issn         = {{1651-2057}},
  keywords     = {{Humans; Dermatitis, Atopic/drug therapy; Sweden; Severity of Illness Index; Registries; Eczema; Quality of Life}},
  language     = {{eng}},
  month        = {{04}},
  pages        = {{1--7}},
  publisher    = {{Medical Journals Limited}},
  series       = {{Acta Dermato-Venereologica}},
  title        = {{Establishment and Utility of SwedAD : A Nationwide Swedish Registry for Patients with Atopic Dermatitis Receiving Systemic Pharmacotherapy}},
  url          = {{http://dx.doi.org/10.2340/actadv.v103.7312}},
  doi          = {{10.2340/actadv.v103.7312}},
  volume       = {{103}},
  year         = {{2023}},
}